Abstract
Stage 2 enrollment complete: Sitravatinib in combination with Nivolumab in NSCLC patients progressing on prior checkpoint inhibitor therapy
Register to see more suggestions
Mendeley helps you to discover research relevant for your work.
Already have an account? Sign in
Sign up for freeCite
CITATION STYLE
APA
Leal, T. A., Spira, A. I., Blakely, C., He, K., Berz, D., Richards, D., … Horn, L. (2018). Stage 2 enrollment complete: Sitravatinib in combination with nivolumab in NSCLC patients progressing on prior checkpoint inhibitor therapy. Annals of Oncology, 29, viii400–viii401. https://doi.org/10.1093/annonc/mdy288.002
Readers over time
Readers' Seniority
Readers' Discipline
